We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs. Our goal is to bring life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies to generate a broad portfolio of highly differentiated product candidates. A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies.
Kazan, Russia
Founded in 2016
11-50 Employees
Working industry
Biotechnology
Type of company
-
Ownership structure
Privately Held
Locations
2 Locations
Number of products
3 Products
Number of services
3 Services
Specialised areas
Therapeutics, Oncology, Biotechnology, TPD, Targeted protein degradation, Health Care
Orum Therapeutics offers a wide range of products and services
Service
Orum Therapeutics Appoints Greg Dwyer as Head of Business Development and Tina Karunaratne as Head of Clinical Operations — Orum Therapeutics
Go to product >
Product
Orum Therapeutics Announces $30 Million Series B Financing — Orum Therapeutics
Go to product >
Service
Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b Inhibitor-PD-1 Conjugate, and Presents New Data Supporting Clinical Development of Two GSPT1 Programs — Orum Therapeutics
Go to product >
Service
Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors — Orum Therapeutics
Go to product >
Product
Orum Therapeutics Raises $8 Million Series A Financing to Advance Cell-Penetrating Antibody Technology for Novel Cancer Therapeutics — Orum Therapeutics
Go to product >
Product
UBS Virtual Biotechnology Private Company Symposium, New York, 21-22 Sep 2022 — Orum Therapeutics
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
Russia
Overall risk estimation:
Medium
The ESG Data of countries are based on public sources
Environment
B
Grade (A-E)
View details
Social
C
Grade (A-E)
View details
Governance
E
Grade (A-E)
View details
Get insights into the use cases of Orum Therapeutics
Use case
Project Manager (PM) - Daejeon, Korea — Orum Therapeutics
JOB TITLE Project Manager (PM) Location Daejeon, Korea Company Overview Orum Therapeutics is a global biotech pioneering the precise delivery of targeted protein degraders and other next generation ADC payloads to improve the treatment of cancer. The compa
Use case
Project Leader - Translational Pharmacology — Orum Therapeutics
JOB TITLE Project Leader – Translational Pharmacology Location: Cambridge, MA Company Overview Orum Therapeutics is a global biotech pioneering the precise delivery of targeted protein degraders and other next generation ADC payloads to improve the treatment of cancer.
Orum Therapeutics operates in 2 countries around the world
Get an overview of the locations of Orum Therapeutics
Location
Country
State
City
Headquarter
Russia
Tatarstan
Kazan
North America
United States
Massachusetts
Cambridge
Some frequent questions that have been asked about Orum Therapeutics
Where is Orum Therapeutics located?
The company headquarter of Orum Therapeutics is located in Kazan, Tatarstan, Russia. Orum Therapeutics has subsidiaries in United States
How many employees does Orum Therapeutics approximately have?
As of the latest available information Orum Therapeutics has around 11-50 employees worldwide.
When was Orum Therapeutics founded?
Orum Therapeutics was founded in 2016
In which industries does Orum Therapeutics mainly work?
The company Orum Therapeutics has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Orum Therapeutics
16250 - 1st TPD Europe 2020
London, United Kingdom
1-10 Employees
-
As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.
Proteovant Therapeutics
Philadelphia, United States
11-50 Employees
2021
The power of protein degradation is now being realized. This innate cellular process is responsible for maintaining protein homeostasis, and we are now exploiting it to break down the proteins that cause disease. The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Development of the best, most effective medicines for patients requires extensive biology insight, medicinal chemistry experience, drug discovery expertise and cutting-edge computational tools such as artificial intelligence and machine learning. Proteovant is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.
Scorpion Therapeutics
Boston, United States
11-50 Employees
2020
We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy. Delivering superior precision medicines via the integration of advanced technologies and scientific excellence. Our world-class team is comprised of experts in cancer biology, medicinal chemistry, next-generation chemical proteomics, computational chemistry and molecular biophysics, machine learning, and drug development. Our fully integrated discovery platform is built upon the most advanced technologies available for drug discovery, small molecule design, and target identification that we believe will enable us to rapidly create highly selective small molecule compounds against an unprecedented spectrum of targets. Aiming to deliver a fast, precise and lethal strike at cancer’s unique drivers. Together, they have architected a new and innovative approach to target and drug discovery.
Avilar Therapeutics
Waltham, United States
11-50 Employees
-
We are developing ATACs (ASGPR Targeting Chimeras), a novel class of degrader designed to harness a natural endogenous process for protein degradation. We are building an organization that is taking science to new limits and has respect for everyone. We have built a bespoke, integrated, and modular drug discovery platform to enable the design and assembly of ATACs targeting a wide array of extracellular proteins.
Camino Pharma
San Diego, United States
1-10 Employees
2014
Our goal is to discover and develop novel, first-in-class medicines for patients suffering from 1) the most aggressive forms of cancer with currently limited treatment options, and 2) psychiatric disorders that are poorly addressed by current medications, including addiction and treatment resistant depression. Our innovative technology platform allows for exploiting inadequately served targets that require a highly adaptive and specialized approach to drug discovery.
Scopus BioPharma
New York, United States
1-10 Employees
2018
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions.